Rare disease innovation fund axed by NHS England

In Clinical Development, Market Access by Tim Peplow1 Comment

rare disease innovation fund nhs england (flickr: Images_of_Money)

Just two months after it was announced, NHS England has scrapped a £50m innovations commissioning fund that aimed to promote the early entry of new treatments for rare diseases into hospitals.

The fund was announced in August, following a review of innovation in the NHS launched by David Cameron.“It is becoming ever more essential to get your products tested and adopted in the NHS much more quickly” said Cameron, and the aim of the fund was to allow fund applicants to do exactly that. Now that the plug has been pulled, more than 600 applicants – including industry, patient groups and charities – that made submissions for funding will miss out.

NHS England said in an email to fund applicants that financial pressures meant the fund had to be suspended, but that it remained “committed to both leading and facilitating the uptake and spread of innovation”.

Read more at BBC News >

Next: 5 lysosomal storage diseases with orphan drugs in development

Join our discussion on LinkedIn, or leave a comment below. Want more from Total Orphan Drugs? Sign up to our newsletter – it doesn’t cost anything and only takes a minute.

Download the brochure for the World Orphan Drug Congress Europe 2013, 14-15 November 2013, Geneva.

Comments

  1. Kay Parkinson

    Having had two children undiagnosed until they were 15&18 with Alstrom Syndrome, who both subsequently needed heart transplantation as a result……a failure to treat rare diseases is never cost effective. To axe this initiative will cost more than it will save. People with rare diseases have not self harmed unlike smokers, alcholics or obese people, services for these groups expand continually, whilst those who had no choice with their condition receive hardly any funds.

Leave a Comment

Current ye@r *